Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is focused on discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Its product candidates include GEN-011 and GEN-009. GEN-011 is an investigational solid tumor cell therapy candidate, which consists of CD4+ and CD8+ neoantigen-targeted peripheral T cells (NPTs) which are specific for up to 30 antigens, designed to limit tumor escape. GEN-011 consists of T cells extracted from the patient’s peripheral blood and specific for ATLAS-prioritized neoantigens. GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The firm is evaluating its Phase I/IIa of GEN-009.